Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, Agilent to Develop Dx Tests, Extend Supply Pact

NEW YORK (GenomeWeb News) – Agendia and Agilent Technologies announced today that they have extended a supply agreement and intend to collaborate on the development of new in vitro diagnostic tests.
According to a joint statement, the firms will collaborate on developing cancer diagnostic tests that will be run on Agilent microarrays.
In February 2007, Amsterdam, Netherlands-based Agendia received US Food and Drug Administration clearance for its MammaPrint diagnostic for breast cancer recurrence. The test, which is performed on an Agilent microarray, was the first in vitro diagnostic multivariate index assay device approved by the FDA since the agency released a draft guidance in 2006 describing such products.
The partners also announced that Agendia’s products will continue to be supplied on Agilent microarrays through Dec. 31, 2011. Agilent has been manufacturing the components for the Agendia assay since 2003, the firms said.
"We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels,” Yvonne Linney, vice president and general manager of genomics for Santa Clara, Calif.-based Agilent, said in the statement.
Financial terms of the agreements were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.